Botanee Bio-Technology (300957.CH)-The Success of WINONA Cannot Cover up the Concerns on the Outlook
The article analyzed a popular skin care product company Botanee in terms of the market potential, 2021H1 performance, strength, comparison with peers, concerns on sales channels,business and outlook.
Equity Bottom-Up
154 Views, 18 Aug 2021 08:41
SUMMARY(Sign Up to Access)
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- Unlimited Research Summaries
- Personalised Alerts
- Custom Watchlists
- Company Analytics & News
- Events & Webinars
Trusted by:
Already have an account? Sign In Now
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
WHAT’S TRENDING
Top Quartile
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- Huadong Medicine (000963.CH) 2022H1 - Huadong Is Back on Track. If Shares Pullback, Then Be Long15 Aug 2022
- Huadong Medicine Co Ltd (000963.CH) - A “Dark Horse” to Reverse Performance Dilemma30 May 2022
- Bloomage Biotechnology Vs Yunnan Botanee Bio-Technology - Accumulate Richly and Break Forth Vastly24 May 2022
- Botanee Bio-Technology (300957.CH)-The Success of WINONA Cannot Cover up the Concerns on the Outlook18 Aug 2021
- Industry Report - Insights on China Cosmetic Contact Lens Market05 Aug 2021
- Eyebright Medical Technology (688050. CH) - A Good Company but The Valuation Is Too High02 Aug 2021
- Imeik Technology Development (300896.CH) - The Valuation Bubble?19 Jul 2021
- Bloomage Biotechnology (688363.CH) - Opportunities Coexist with Challenges22 Apr 2021
x